EPA:ALCLS - Euronext Paris - Matif - FR0010425595 - Common Stock - Currency: EUR
We assign a fundamental rating of 3 out of 10 to ALCLS. ALCLS was compared to 67 industry peers in the Biotechnology industry. ALCLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALCLS is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.12% | ||
ROE | -41.34% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.64% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.88 | ||
Altman-Z | -0.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.73 | ||
Quick Ratio | 1.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 13.7 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
EPA:ALCLS (7/25/2025, 7:00:00 PM)
2.23
+0.33 (+17.49%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.56 | ||
P/FCF | 13.7 | ||
P/OCF | 11.41 | ||
P/B | 2 | ||
P/tB | 2.02 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.12% | ||
ROE | -41.34% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 4.64% | ||
FCFM | 25.96% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.88 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 19.36% | ||
Cap/Sales | 5.21% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.73 | ||
Quick Ratio | 1.73 | ||
Altman-Z | -0.8 |